

WHO guideline on the use
of safety-engineered syringes
for intramuscular, intradermal
and subcutaneous injections
in health care settings



WHO Library Cataloguing-in-Publication Data

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings.

1. Injections, Subcutaneous – standards. 2. Injections, Intradermal – standards. 3. Injections, Intramuscular – standards. 4. Syringes. 5. Needlestick Injuries – prevention and control. 6. Delivery of Health Care. 7. Guideline. I. World Health Organization.

ISBN 978 92 4 154982 0

(NLM classification: W 26)

© **World Health Organization 2016**

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

CONTENTS

Acknowledgements	2
Abbreviations and acronyms	6
Executive summary	7
Scope and purpose	12
Target audience	13
Background	14
Methodology	24
Guideline development process	28
Guideline Steering Committee	29
Guideline Development Group	29
Management of conflicts of interest	32
Recommendations	33
Question 1: Recommendation for the use of sharp injury protection syringes (SIPs) for intramuscular, intradermal and subcutaneous injections	33
Question 2: Recommendation for the use of re-use prevention syringes (RUPs) for intramuscular, intradermal and subcutaneous injections	35
Implications for future research	37
Considerations for the development of future guidelines	39
Dissemination, adaptation and implementation	40
Dissemination	41
Adaptation and implementation	41
Monitoring and evaluation of guideline implementation	43
Plans for updating this guideline	45
References	46

ACKNOWLEDGEMENTS

Many professionals from a range of backgrounds and specialties have contributed to the development of this guidance. WHO is sincerely grateful to them for their time and support.

Guideline Development Group (GDG)

The chair of the GDG was **Gwen Orr Brachman**
Assistant Clinical Professor of Medicine, New Jersey Medical School
International Commission on Occupational Health, USA

The following experts served on the GDG:

- **Arshad Altaf**, Senior Manager, Ethics and Integrity, Research Office, Aga Khan University, Karachi, Pakistan
- **Nagwa Abdel Tawab Hasanin**, Technical Specialist, Health Technology Center (HTC), UNICEF Supply Division, Copenhagen, Denmark
- **Jean Barry**, Consultant, Nursing and Health Policy, International Council of Nurses (ICN), Geneva, Switzerland
- **Odile Frank**, Health and Social Services Officer, Public Services International, Ferney-Voltaire, France
- **Lee-Nah Hsu**, Technical Specialist, HIV/AIDS and the World of Work Branch (ILOAIDS), Conditions of Work and Equality Department (WORKQUALITY), International Labour Organization (ILO), Geneva, Switzerland
- **Angela Laramie**, Epidemiologist, Sharps Injury Surveillance Project, Occupational Health Surveillance Program, Massachusetts Department of Public Health, USA
- **Robert Matthews**, Contracts Manager, Health Technology Centre (HTC), UNICEF Supply Division, Copenhagen, Denmark

External reviewers:

We thank the following experts for reviewing the final guideline document and providing valuable input:

- **Valentina Laurenzia Ancona**, Manager, Government Affairs & Public Policy, EUCOMED Medical Technology, Brussels, Belgium
- **William Buchta**, Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Minnesota, USA
- **William Dierick**, Technology Development Manager, Terumo, Antwerp, Belgium
- **Kathryn Duesman**, Executive Director, Global Health, Retractable Technologies, Little Elm, TX, USA
- **Renuka Gadde**, Vice-President, Global Health at BD, Greater New York City Area, USA
- **Maria Ganczak**, Associate Professor, Specialist in internal medicine, Specialist in infectious diseases, Specialist in epidemiology, Department of Public Health, Faculty of Medical Sciences, Pomeranian Medical University, Szczecin, Poland
- **Charles Gore**, Chief Executive, The Hepatitis C Trust, London, UK
- **Anisa Ismail**, Improvement Specialist, HIV, USAID Applying Science to Strengthen and Improve Systems Project (ASSIST), University Research Co, LLC, Bethesda, MD, USA
- **Petra Keil**, Head Global Public Policy, Novartis International AG, Basel, Switzerland
- **Marc Koska**, OBE, LifeSaver Campaign Founder, The Safepoint Trust, Pippingford, East Sussex, UK
- **Ed Krisiunas**, Owner, “Waste Not, Want Not” International (NWN), Hartford, CT, USA
- **Elayne Kornblatt Phillips**, Clinical Associate Professor University of Virginia School of Nursing, Charlottesville, VA, USA
- **Judith Landau**, ARISE Founder, CEO & President, Boulder, CO, USA
- **Rashad Massoud**, Director USAID Health Care Improvement Project, Director USAID Applying Science to Strengthen and Improve Systems Project, Senior Vice President Quality & Performance Institute, University Research Co LLC Center for Human Services, Bethesda, MD, USA
- **Shaheen Mehtar**, FRC Path (UK), FC-Path (Micro) (SA), MD (Eng) Chair Infection Control Africa Network (ICAN), Extraordinary Professor Div Community Health Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa

- **Nancy Muller**, Programme Officer at PATH, Seattle, WA, USA
- **Babacar Ndoye**, Expert Consultant, Formateur, Hygiène hospitalière/Contrôle des infections/Sécurité des patients, Dakar, Senegal
- **Joseph Perz**, Team Leader, Quality Standards & Safety (Proposed), Prevention and Response Branch, Division of Healthcare Quality Promotion Centers for Disease Control and Prevention, Atlanta, GA, USA
- **Glenn Post**, Senior Medical Advisor USAID Office of HIV/AIDS, Washington DC, USA
- **Cristiane Rapparini**, Riscobiologico.org, Rio de Janeiro, RJ, Brazil
- **Abimbola O. Sowande**, Consultant/Expert, Injection Safety/HCWM in the context of IPC (Infection Prevention and Control), Regional Coordinator, Board of Trustees, International Federation Infection Control (IFIC), Surulere, Lagos, Nigeria
- **Ruth Stringer**, Research Scientist, International Science and Policy Coordinator Health Care Without Harm, Exeter, UK
- **Darin Zehrung**, Portfolio Leader, Vaccine Delivery Technologies PATH, Seattle, WA, USA

WHO Steering Committee

- **Marie-Paule Kieny**, Assistant Director-General, Health Systems and Innovation (HIS)
- **Edward Kelley**, Director, Department of Service Delivery and Safety (SDS), Health Systems and Innovation (HIS)
- **Selma Khamassi**, Medical Officer, Department of Service Delivery and Safety (SDS), Health Systems and Innovation (HIS)
- **Benedetta Allegranzi**, Technical Officer, Department of Service Delivery and Safety (SDS), Health Systems and Innovation (HIS)
- **Denis Maire**, Scientist, Department of Essential Medicines and Health Products Prequalification Team, Health Systems and Innovation (HIS)
- **Mwansa Nkowane**, Technical Officer, Department of Health Work Force (HWF), Health Systems and Innovation (HIS)
- **Sergey Eremin**, Medical Officer, Department of Pandemic and Epidemic Diseases (PED), Health Security and Environment (HSE)
- **Hande Harmanci**, Medical Officer, Global Hepatitis Programme, HIV Department, HIV, Tuberculosis and Malaria (HTM)

- **Susan Wilburn**, Technical Officer, Department of Public Health, Environmental and Social Determinants (PHE), Occupational Health Programme, Health Security and Environment (HSE)
- **Lisa Hedman**, Technical Officer, Department of Essential Medicines and Health Products, Policy Access and Use Unit (PAU), Health Systems and Innovation (HIS)

Temporary advisers

We would like to credit the following researchers for developing, in collaboration with the technical officer in charge, the initial scoping document and for conducting all systematic reviews, evidence profiles and GRADE tables:

- **Elie Akl**, Department of Internal Medicine, American University of Beirut
- **Alain Harb**, Lebanese University, Lebanon
- **Rami Tarabay**, Lebanese University, Lebanon
- **Batoul Diab**, Lebanese University, Lebanon
- **Rami A. Ballout**, American University of Beirut

We would like to thank **Susan L. Norris**, GRC Secretariat, for providing a technical presentation at the GDG meeting on the WHO guidelines' development process and for her guidance and support throughout the development of this guideline.

Chairperson and methodologist

We would like to acknowledge the work of **Gwen Orr Brachman** for chairing the Guidelines Development Group. We thank **Elie Akl** for serving as methodologist and who oversaw the development of the PICO questions and the conduct of the systematic reviews, developed the evidence profiles and the GRADE tables.

The first drafts of the guidelines were written by **Selma Khamassi**, SDS Department. Drafts were reviewed and inputs provided by members of the GDG, peer reviewers and WHO Secretariat staff. The final draft was edited by **Laura Pearson**, SDS Department and **Lisa Hedman**, EMP Department.

Overall coordination

Selma Khamassi

ABBREVIATIONS AND ACRONYMS

AD	auto-disable syringe
AEFI	adverse events following injections
AIDS	acquired immunodeficiency syndrome
CDC	Centers for Disease Control and Prevention
EPSU	European Public Service Union
EU	European Union
EUCOMED	European Medical Technology Industry Association
FDA	Food and Drug Administration
FTE	full-time equivalent employee
GAVI	Global Alliance for Vaccines and Immunization
GBD	global burden of disease
GDG	Guideline Development Group
HBV	hepatitis B virus
HCV	hepatitis C virus
HIV	human immunodeficiency virus
HCW	health care worker
HOSPEEM	European Hospital and Healthcare Employers' Association
ID	intradermal
ILO	International Labour Office
IM	intramuscular
ISO	International Organization for Standardization
IV	intravenous
LMICs	low- and middle-income countries
MS	Member State
NIOSH	CDC National Institute for Occupational Safety and Health

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27148

